55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an update on the extension study portion of the ISO-CC-005 Phase I/IIa study. New data following 16-weeks of treatment and beyond shows best Overall Response Rate (ORR) of 55% in 31 patients. The results are in line with the targeted readout in the ongoing global Phase III study, AGENT.

55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study Read More »